{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chang YH"],"funding":["Academia Sinica"],"pagination":["e179726"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11141937"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(10)"],"pubmed_abstract":["Since its emergence, SARS-CoV-2 has been continuously evolving, hampering the effectiveness of current vaccines against COVID-19. mAbs can be used to treat patients at risk of severe COVID-19. Thus, the development of broadly protective mAbs and an understanding of the underlying protective mechanisms are of great importance. Here, we isolated mAbs from donors with breakthrough infection with Omicron subvariants using a single-B cell screening platform. We identified a mAb, O5C2, which possesses broad-spectrum neutralization and antibody-dependent cell-mediated cytotoxic activities against SARS-CoV-2 variants, including EG.5.1. Single-particle analysis by cryo-electron microscopy revealed that O5C2 targeted an unusually large epitope within the receptor-binding domain of spike protein that"],"journal":["JCI insight"],"pubmed_title":["Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody."],"pmcid":["PMC11141937"],"funding_grant_id":["AS-IDR-112-13 to K.IL.,AS-CDA-109-L08","S.T.D.H,AS-KPQ-111-KNT","AS-IDR-11-04 to S.T.D.H","Intramural funds to K.IL."],"pubmed_authors":["Chang CS","Wu MH","Kong WL","Tsai HY","Liao CC","Lin KI","Lin YL","Huang CH","Kuo Y","Lu MJ","Chen AY","Chou YC","Tung CP","Chang YH","Hsu SD","Chang LY","Angata T","Bai LY","Hsu MF","Liang JJ","Chen CC","Chang YC","Chen WN","Chang FJ","Yu JH","Chen YH"],"additional_accession":[]},"is_claimable":false,"name":"Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody.","description":"Since its emergence, SARS-CoV-2 has been continuously evolving, hampering the effectiveness of current vaccines against COVID-19. mAbs can be used to treat patients at risk of severe COVID-19. Thus, the development of broadly protective mAbs and an understanding of the underlying protective mechanisms are of great importance. Here, we isolated mAbs from donors with breakthrough infection with Omicron subvariants using a single-B cell screening platform. We identified a mAb, O5C2, which possesses broad-spectrum neutralization and antibody-dependent cell-mediated cytotoxic activities against SARS-CoV-2 variants, including EG.5.1. Single-particle analysis by cryo-electron microscopy revealed that O5C2 targeted an unusually large epitope within the receptor-binding domain of spike protein that","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-01T20:22:24.074Z","creation":"2026-05-22T03:08:32.039Z"},"accession":"S-EPMC11141937","cross_references":{"pubmed":["38775156"],"doi":["10.1172/jci.insight.179726"]}}